Gail Murphy

1.3k total citations
23 papers, 1.0k citations indexed

About

Gail Murphy is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Molecular Biology. According to data from OpenAlex, Gail Murphy has authored 23 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Endocrinology, Diabetes and Metabolism, 5 papers in Surgery and 5 papers in Molecular Biology. Recurrent topics in Gail Murphy's work include Growth Hormone and Insulin-like Growth Factors (4 papers), Nausea and vomiting management (3 papers) and Renal Transplantation Outcomes and Treatments (2 papers). Gail Murphy is often cited by papers focused on Growth Hormone and Insulin-like Growth Factors (4 papers), Nausea and vomiting management (3 papers) and Renal Transplantation Outcomes and Treatments (2 papers). Gail Murphy collaborates with scholars based in United States, Netherlands and Sweden. Gail Murphy's co-authors include Ronald I. Clyman, David Krupa, K. Cerchio, William J. Polvino, Deborah Panebianco, Johan Svensson, Robert J. Gould, B. Gertz, Daniel F. Wyss and John‐Olov Jansson and has published in prestigious journals such as The Journal of Clinical Endocrinology & Metabolism, Journal of Bone and Mineral Research and SLEEP.

In The Last Decade

Gail Murphy

23 papers receiving 985 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gail Murphy United States	16	272	260	249	204	188	23	1.0k
Deborah Panebianco United States	22	155 0.6×	351 1.4×	74 0.3×	32 0.2×	57 0.3×	64	1.4k
Masanari Shiramoto Japan	19	121 0.4×	483 1.9×	203 0.8×	62 0.3×	256 1.4×	41	1.7k
Rainer Zimmermann Germany	19	80 0.3×	274 1.1×	66 0.3×	315 1.5×	33 0.2×	47	1.2k
Stefanie Friedrich Germany	16	493 1.8×	235 0.9×	519 2.1×	190 0.9×	307 1.6×	50	1.6k
Jin Shang China	17	220 0.8×	137 0.5×	113 0.5×	32 0.2×	35 0.2×	37	1.5k
Oliver Blankenstein Germany	28	249 0.9×	491 1.9×	220 0.9×	97 0.5×	1.1k 6.0×	89	2.1k
Avivit Peer Israel	16	42 0.2×	104 0.4×	40 0.2×	139 0.7×	102 0.5×	71	1.1k
Satoru Takagi Japan	19	372 1.4×	172 0.7×	98 0.4×	42 0.2×	318 1.7×	53	1.2k
Hiroki Matsumoto Japan	14	73 0.3×	349 1.3×	32 0.1×	253 1.2×	32 0.2×	64	877
Roser Ferrer Spain	18	374 1.4×	302 1.2×	65 0.3×	18 0.1×	241 1.3×	99	1.1k

Countries citing papers authored by Gail Murphy

Since Specialization

Citations

This map shows the geographic impact of Gail Murphy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gail Murphy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gail Murphy more than expected).

Fields of papers citing papers by Gail Murphy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gail Murphy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gail Murphy. The network helps show where Gail Murphy may publish in the future.

Co-authorship network of co-authors of Gail Murphy

This figure shows the co-authorship network connecting the top 25 collaborators of Gail Murphy. A scholar is included among the top collaborators of Gail Murphy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gail Murphy. Gail Murphy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wring, Stephen A., et al.. (2018). Lack of Impact by SCY‐078, a First‐in‐Class Oral Fungicidal Glucan Synthase Inhibitor, on the Pharmacokinetics of Rosiglitazone, a Substrate for CYP450 2C8, Supports the Low Risk for Clinically Relevant Metabolic Drug‐Drug Interactions. The Journal of Clinical Pharmacology. 58(10). 1305–1313. 33 indexed citations

Sun, Hong, William P. Kennedy, Darren Wilbraham, et al.. (2013). Effects of Suvorexant, an Orexin Receptor Antagonist, on Sleep Parameters as Measured by Polysomnography in Healthy Men. SLEEP. 36(2). 259–67. 132 indexed citations

Tatosian, Daniel, Anup Majumdar, Erica S. Klaassen, et al.. (2013). Placebo- and Amitriptyline-Controlled Evaluation of Central Nervous System Effects of the NK₁Receptor Antagonist Aprepitant and Intravenous Alcohol Infusion at Pseudo-Steady State. The Journal of Clinical Pharmacology. 53(8). 846–856. 3 indexed citations

Clyman, Ronald I., et al.. (2012). Patent Ductus Arteriosus: Are Current Neonatal Treatment Options Better or Worse Than No Treatment at All?. Seminars in Perinatology. 36(2). 123–129. 203 indexed citations

Stroh, Mark, Xiaodong Li, Deborah Panebianco, et al.. (2012). The minimal impact of food on the pharmacokinetics of ridaforolimus. Cancer Chemotherapy and Pharmacology. 70(1). 177–182. 4 indexed citations

Stroh, Mark, John Palcza, Jacqueline B. McCrea, et al.. (2012). The effect of multiple doses of rifampin and ketoconazole on the single-dose pharmacokinetics of ridaforolimus. Cancer Chemotherapy and Pharmacology. 69(5). 1247–1253. 5 indexed citations

Iannone, Raffaele, B.R. Bloem, John Palcza, et al.. (2011). The effects of a novel histamine-3 receptor inverse agonist on essential tremor in comparison to stable levels of alcohol. Journal of Psychopharmacology. 26(2). 292–302. 16 indexed citations

Marbury, Thomas, Bo Jin, Deborah Panebianco, et al.. (2011). Pharmacokinetics of Oral Dexamethasone and Midazolam When Administered With Single-Dose Intravenous 150 mg Fosaprepitant in Healthy Adult Subjects. The Journal of Clinical Pharmacology. 51(12). 1712–1720. 27 indexed citations

Loos, Walter J., Ronald de Wit, Steven J. Freedman, et al.. (2006). Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients. Cancer Chemotherapy and Pharmacology. 59(3). 407–412. 40 indexed citations

10.

Bergman, Arthur, Joanne Burke, Patrick Larson, et al.. (2006). Effects of Ezetimibe on Cyclosporine Pharmacokinetics in Healthy Subjects. The Journal of Clinical Pharmacology. 46(3). 321–327. 23 indexed citations

11.

Bergman, Arthur, Joanne Burke, Patrick Larson, et al.. (2006). Interaction of Single‐Dose Ezetimibe and Steady‐State Cyclosporine in Renal Transplant Patients. The Journal of Clinical Pharmacology. 46(3). 328–336. 34 indexed citations

12.

Bergman, Arthur, Amy O. Johnson‐Levonas, Joanne Burke, et al.. (2005). Assessment of pharmacokinetic interactions between ezetimibe and cyclosporine. Clinical Pharmacology & Therapeutics. 77(2). P75–P75. 6 indexed citations

13.

Bergman, Arthur, Gail Murphy, Joanne Burke, et al.. (2004). Simvastatin Does Not Have a Clinically Significant Pharmacokinetic Interaction With Fenofibrate in Humans. The Journal of Clinical Pharmacology. 44(9). 1054–1062. 75 indexed citations

14.

Majumdar, Anup, Jacqueline B. McCrea, John M. Busillo, et al.. (2003). Evaluation of the effect of aprepitant on CYP3A4 activity using midazolam as a probe. Clinical Pharmacology & Therapeutics. 73(2). 3 indexed citations

15.

McCrea, Jacqueline B., Anup Majumdar, John M. Busillo, et al.. (2003). Lack of effect of aprepitant on the pharmacokinetics of ondansetron. Clinical Pharmacology & Therapeutics. 73(2). 2 indexed citations

16.

Codner, Ethel, Fernando Cassorla, Anatoly Tiulpakov, et al.. (2001). Effects of oral administration of ibutamoren mesylate, a nonpeptide growth hormone secretagogue, on the growth hormone–insulin‐like growth factor I axis in growth hormone–deficient children. Clinical Pharmacology & Therapeutics. 70(1). 91–98. 27 indexed citations

17.

Svensson, Johan, Lars Lönn, John‐Olov Jansson, et al.. (1998). Two-Month Treatment of Obese Subjects with the Oral Growth Hormone (GH) Secretagogue MK-677 Increases GH Secretion, Fat-Free Mass, and Energy Expenditure¹. The Journal of Clinical Endocrinology & Metabolism. 83(2). 362–369. 125 indexed citations

18.

Chapman, Ian, Ora Hirsch Pescovitz, Gail Murphy, et al.. (1997). Oral Administration of Growth Hormone (GH) Releasing Peptide-Mimetic MK-677 Stimulates the GH/Insulin-Like Growth Factor-I Axis in Selected GH-Deficient Adults¹. The Journal of Clinical Endocrinology & Metabolism. 82(10). 3455–3463. 49 indexed citations

19.

Barrett, Jeffrey S., Gail Murphy, Kathelijne Peerlinck, et al.. (1994). Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein-IIb/IIIa receptor antagonist, in healthy men. Clinical Pharmacology & Therapeutics. 56(4). 377–388. 111 indexed citations

20.

Peck, Carl C., Dale P. Conner, Ramona G. Almirez, et al.. (1988). Outward Transcutaneous Chemical Migration: Implications for Diagnostics and Dosimetry. Skin Pharmacology and Physiology. 1(1). 14–23. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact